Literature DB >> 19109366

High-salt diet enhances mouse aortic relaxation through adenosine A2A receptor via CYP epoxygenases.

Mohammed A Nayeem1, Dovenia S Ponnoth, Matthew A Boegehold, Darryl C Zeldin, John R Falck, S Jamal Mustafa.   

Abstract

We hypothesize that A(2A) adenosine receptors (A(2A) AR) promote aortic relaxation in mice through cytochrome P450 (CYP)-epoxygenases and help to avoid salt sensitivity. Aortas from male mice maintained on a high-salt (HS; 7% NaCl) or normal-salt (NS; 0.45% NaCl) diet for 4-5 wks were used. Concentration-response curves (10(-11)-10(-5) M) for 5'-N-ethylcarboxamidoadenosine (NECA; a nonselective adenosine analog) and CGS 21680 (A(2A) AR agonist) were obtained with different antagonists including ZM 241385 (A(2A) AR antagonist; 10(-6) M), SCH 58261 (A(2A) AR antagonist; 10(-6) M), N(omega)-nitro-l-arginine methyl ester (l-NAME; endothelial nitric oxide synthase inhibitor; 10(-4) M) and inhibitors including methylsulfonyl-propargyloxyphenylhexanamide (MS-PPOH; CYP epoxygenases inhibitor; 10(-5)M), 14,15-epoxyeicosa-5(z)-enoic acid (14,15-EEZE; EET antagonist; 10(-5)M), dibromo-dodecenyl-methylsulfimide (DDMS; CYP4A inhibitor; 10(-5)M), and HET0016 (20-HETE inhibitor; 10(-5)M). At 10(-7) M of NECA, significant relaxation in HS (+22.58 +/- 3.12%) was observed compared with contraction in NS (-10.62 +/- 6.27%, P < 0.05). ZM 241385 changed the NECA response to contraction (P < 0.05) in HS. At 10(-7) M of CGS 21680, significant relaxation in HS (+32.04 +/- 3.08%) was observed compared with NS (+10.45 +/- 1.34%, P < 0.05). SCH 58261, l-NAME, MS-PPOH, and 14,15-EEZE changed the CGS 21680-induced relaxation to contraction (P < 0.05) in HS. Interestingly, DDMS and HET0016 changed CGS 21680 response to relaxation (P < 0.05) in NS; however, there was no significant difference found between DDMS, HET0016-treated HS and NS vs. nontreated HS group (P > 0.05). CYP2C29 protein was 55% and 74% upregulated in HS vs. NS (P < 0.05) mice aorta and kidney, respectively. CYP4A protein was 30.30% and 35.70% upregulated in NS vs. HS (P < 0.05) mice aorta and kidneys, respectively. A(1) AR was downregulated, whereas A(2A) AR was upregulated in HS compared with NS. These data suggest that HS may activate CYP2C29 via A(2A) AR, causing relaxation, whereas NS may contribute to the upregulation of CYP4A causing contraction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109366      PMCID: PMC2665852          DOI: 10.1152/ajpregu.90798.2008

Source DB:  PubMed          Journal:  Am J Physiol Regul Integr Comp Physiol        ISSN: 0363-6119            Impact factor:   3.619


  50 in total

1.  Expression of adenosine receptors in the preglomerular microcirculation.

Authors:  Edwin K Jackson; Chongxue Zhu; Stevan P Tofovic
Journal:  Am J Physiol Renal Physiol       Date:  2002-07

2.  Decreased renal cytochrome P450 2C enzymes and impaired vasodilation are associated with angiotensin salt-sensitive hypertension.

Authors:  Xueying Zhao; David M Pollock; Edward W Inscho; Darryl C Zeldin; John D Imig
Journal:  Hypertension       Date:  2002-12-16       Impact factor: 10.190

3.  Comparison of the vascular effects of adenosine in isolated mouse heart and aorta.

Authors:  M A Hassan Talukder; R Ray Morrison; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-01       Impact factor: 4.733

4.  Adenosine production in the ischemic kidney.

Authors:  W L Miller; R A Thomas; R M Berne; R Rubio
Journal:  Circ Res       Date:  1978-09       Impact factor: 17.367

5.  Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors.

Authors:  R Ray Morrison; M A Hassan Talukder; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

6.  Mechanisms of delayed preconditioning with A1 adenosine receptor activation in porcine coronary smooth muscle cells.

Authors:  Mohammed A Nayeem; S Jamal Mustafa
Journal:  Pol J Pharmacol       Date:  2002 Sep-Oct

7.  Protein kinase C isoforms and A1 adenosine receptors in porcine coronary smooth muscle cells.

Authors:  Mohammed A Nayeem; S Jamal Mustafa
Journal:  Vascul Pharmacol       Date:  2002-07       Impact factor: 5.773

8.  Ischemic and pharmacological preconditioning induces further delayed protection in transgenic mouse cardiac myocytes over-expressing adenosine A1 receptors (A1AR): role of A1AR, iNOS and K(ATP) channels.

Authors:  Mohammed A Nayeem; G Paul Matherne; S Jamal Mustafa
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-02-25       Impact factor: 3.000

9.  Epoxyeicosatrienoic acids mediate adenosine-induced vasodilation in rat preglomerular microvessels (PGMV) via A2A receptors.

Authors:  M K Cheng; A B Doumad; H Jiang; J R Falck; J C McGiff; M A Carroll
Journal:  Br J Pharmacol       Date:  2004-01-12       Impact factor: 8.739

10.  Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases.

Authors:  Xueying Zhao; David M Pollock; Darryl C Zeldin; John D Imig
Journal:  Hypertension       Date:  2003-08-04       Impact factor: 10.190

View more
  17 in total

1.  Role of ω-hydroxylase in adenosine-mediated aortic response through MAP kinase using A2A-receptor knockout mice.

Authors:  Dovenia S Ponnoth; Mohammed A Nayeem; Swati S Kunduri; Stephen L Tilley; Darryl C Zeldin; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-07       Impact factor: 3.619

2.  Contributions of A2A and A2B adenosine receptors in coronary flow responses in relation to the KATP channel using A2B and A2A/2B double-knockout mice.

Authors:  Maryam Sharifi Sanjani; Bunyen Teng; Thomas Krahn; Stephen Tilley; Catherine Ledent; S Jamal Mustafa
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-09-23       Impact factor: 4.733

3.  Modulation by salt intake of the vascular response mediated through adenosine A(2A) receptor: role of CYP epoxygenase and soluble epoxide hydrolase.

Authors:  Mohammed A Nayeem; Darryl C Zeldin; Matthew A Boegehold; Christophe Morisseau; Anne Marowsky; Dovenia S Ponnoth; Kevin P Roush; John R Falck
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-04-28       Impact factor: 3.619

4.  Drug Delivery and Nanoformulations for the Cardiovascular System.

Authors:  W J Geldenhuys; M T Khayat; J Yun; M A Nayeem
Journal:  Res Rev Drug Deliv       Date:  2017-03-07

5.  Deletion of soluble epoxide hydrolase enhances coronary reactive hyperemia in isolated mouse heart: role of oxylipins and PPARγ.

Authors:  Ahmad Hanif; Matthew L Edin; Darryl C Zeldin; Christophe Morisseau; Mohammed A Nayeem
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-08-03       Impact factor: 3.619

6.  Protease-activated receptor 2 protects against myocardial ischemia-reperfusion injury through the lipoxygenase pathway and TRPV1 channels.

Authors:  Beihua Zhong; Shuangtao Ma; Donna H Wang
Journal:  Exp Ther Med       Date:  2019-09-09       Impact factor: 2.447

7.  High salt diet exacerbates vascular contraction in the absence of adenosine A₂A receptor.

Authors:  Isha Pradhan; Darryl C Zeldin; Catherine Ledent; Jamal S Mustafa; John R Falck; Mohammed A Nayeem
Journal:  J Cardiovasc Pharmacol       Date:  2014-05       Impact factor: 3.105

Review 8.  Role of oxylipins in cardiovascular diseases.

Authors:  Mohammed A Nayeem
Journal:  Acta Pharmacol Sin       Date:  2018-06-07       Impact factor: 6.150

9.  Salt modulates vascular response through adenosine A(2A) receptor in eNOS-null mice: role of CYP450 epoxygenase and soluble epoxide hydrolase.

Authors:  Mohammed A Nayeem; Darryl C Zeldin; Matthew A Boegehold; John R Falck
Journal:  Mol Cell Biochem       Date:  2010-12-14       Impact factor: 3.396

10.  Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ.

Authors:  Mohammed A Nayeem; Isha Pradhan; S Jamal Mustafa; Christophe Morisseau; John R Falck; Darryl C Zeldin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-11-14       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.